TLSI · TriSalus Life Sciences, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|
| $54M – $57M | $45.08M | $45.15M | $29.43M | $18.51M | $12.4M | — | |
| — | $6.41M | $6.97M | $4.1M | $2.61M | $2.26M | — | |
| — | $38.67M | $38.19M | $25.33M | $15.91M | $10.14M | — | |
| — | — | 84.57% | 86.06% | 85.93% | 81.79% | — | |
| — | $14.63M | $14.97M | $17.69M | $29.84M | $21.36M | — | |
| — | $33.64M | $28.71M | $25.84M | $17.03M | $12.74M | — | |
| — | $20.91M | $21.46M | $17.97M | $23.51M | $12.48M | $3.04M | |
| — | — | — | — | $18K | $122K | — | |
| — | $560K | $626K | $744K | $684K | $398K | — | |
| — | -$30.51M | -$26.95M | -$36.17M | -$54.48M | -$36.44M | -$3.04M | |
| — | — | -59.68% | -122.88% | -294.28% | -293.91% | — | |
| — | -$29.95M | -$26.32M | -$35.42M | -$53.79M | -$36.04M | — | |
| — | $5.84M | $5.54M | $3.09M | $16K | $1000 | — | |
| — | $968K | $555K | $404K | $431K | $180K | $64K | |
| — | -$151K | -$456K | -$312K | -$378K | $8.86M | $7.81M | |
| — | -$28.2M | -$39.22M | -$30.04M | -$59.35M | -$47.18M | $4.77M | |
| — | $13K | $7000 | $6000 | $9000 | $9000 | $0 | |
| — | -$28.21M | -$39.23M | -$30.05M | -$59.36M | -$47.19M | $4.77M | |
| — | — | -86.88% | -102.09% | -320.69% | -380.6% | — | |
| — | -$57.25M | -$69.69M | -$33.23M | -$63.6M | -$50.02M | — | |
| USD/shares | — | -$1.31 | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
| USD/shares | — | -$1.31 | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent debt carrying amount | 2026-06-30 | USD 33,065,000 | 10-Q filed 2026-08-06 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 80 similar-size Medical Devices companies (of 150 listed).